NIH study’s focus on antibodies used to measure the extent of undetected transmission
The National Institutes of Health announced that it will look at antibodies to help understand just how far the coronavirus has subtly spread through the population.
In a “serosurvey” analyzing the blood samples of up to 10,000 volunteers, NIH said the presence of SARS-CoV-2 antibodies serve as a sign that the body had encountered the disease and developed a response to it.
“An antibody test is looking back into the immune system’s history with a rearview mirror,” Dr. Matthew J. Memoli, the principal investigator of the study, said in a news release. “By analyzing an individual’s blood, we can determine if that person has encountered SARS-CoV-2 previously.”
NIH said the molecular tests that are commonly done by inserting a cotton swab into someone’s nose can identify a current infection, but they can’t tell whether a person was previously infected with COVID-19 and recovered.
A positive test for the SARS-CoV-2 antibodies confirms that they already had the disease.
“This study will give us a clearer picture of the true magnitude of the COVID-19 pandemic in the United States by telling us how many people in different communities have been infected without knowing it, because they had a very mild, undocumented illness or did not access testing while they were sick,” according to Dr. Anthony S. Fauci, director for the National Institute of Allergy and Infectious Diseases. “These crucial data will help us measure the impact of our public health efforts and guide our COVID-19 response moving forward.”
Healthy volunteers over the age of 18 from anywhere in the U.S. can participate, and will be asked to consent to enrollment over phone.
People with a confirmed history of coronavirus or current symptoms consistent with COVID-19 are not eligible to participate.
People interested in joining this study should contact
clinicalstudiesunit@nih.gov. For more information, visit
ClinicalTrials.gov using identifier NCT04334954.